What is Dabigatran?
Dabigatran is an oral direct thrombin (factor IIa) inhibitor anticoagulant that works by competitively and reversibly blocking thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting clot formation. 1
Mechanism of Action
Dabigatran and its acyl glucuronides directly and competitively inhibit thrombin (factor IIa), a serine protease critical in the coagulation cascade. By blocking thrombin, dabigatran prevents:
- Conversion of fibrinogen into fibrin
- Thrombin-induced platelet aggregation
- Both free and clot-bound thrombin activity 1
The drug is administered as dabigatran etexilate, a prodrug that is rapidly converted to the active form dabigatran. Importantly, this conversion is independent of cytochrome P-450 enzymes, making drug-drug and drug-diet interactions significantly less likely compared to warfarin. 2, 3
FDA-Approved Indications
Dabigatran is indicated for:
- Reducing stroke and systemic embolism risk in adult patients with non-valvular atrial fibrillation
- Treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults who have been treated with parenteral anticoagulant for 5-10 days
- Reducing recurrence risk of DVT and PE in adults previously treated 1
Key Clinical Characteristics
Pharmacokinetics
- Bioavailability: 3-7% (oral absorption)
- Peak concentration: 1 hour post-administration (fasted state)
- Elimination: Predominantly renal (making renal function critical for dosing)
- Protein binding: Low (~35%), allowing for hemodialysis removal if needed
- Half-life accumulation: Approximately 2-fold with twice-daily dosing 1
Advantages Over Warfarin
- Fixed-dose regimen without routine laboratory monitoring (no INR checks required)
- Rapid onset of action
- Predictable pharmacokinetic profile
- Minimal food and drug interactions
- Significantly lower intracranial hemorrhage risk compared to warfarin 2, 4, 5
Clinical Evidence Base
The landmark RE-LY trial (18,113 patients with non-valvular atrial fibrillation) demonstrated:
- 150 mg twice daily: 34% reduction in stroke/systemic embolism versus warfarin (1.11% vs 1.71% per year, P<0.001), with no increase in major bleeding
- 110 mg twice daily: Non-inferior to warfarin for stroke prevention (1.54% vs 1.71% per year) with 20% reduction in major bleeding (2.87% vs 3.57% per year, P<0.003) 2, 3
Guideline Recommendations
The 2011 ACCF/AHA/HRS guidelines give dabigatran a Class I recommendation as an alternative to warfarin for stroke prevention in atrial fibrillation patients with risk factors for stroke who do NOT have:
- Prosthetic heart valves
- Hemodynamically significant valve disease
- Severe renal failure (creatinine clearance <15 mL/min)
- Advanced liver disease with impaired baseline clotting function 2, 3
Monitoring and Reversal
Laboratory Effects
Dabigatran prolongs:
- aPTT (provides approximation of anticoagulant effect)
- ECT (ecarin clotting time - more specific measure than aPTT)
- TT and dTT
Note: INR is relatively insensitive to dabigatran and cannot be interpreted the same way as with warfarin 1
Reversal Agent
A specific reversal agent (idarucizumab) is FDA-approved and available for emergency reversal in adult patients. 1, 5 In overdose situations, hemodialysis can remove approximately 49-57% of dabigatran over 4 hours using high-flux dialysis 1
Critical Contraindications and Precautions
Avoid dabigatran in patients with:
- Prosthetic heart valves or hemodynamically significant valvular disease
- Severe renal dysfunction (CrCl <30 mL/min in most contexts; <15 mL/min per guidelines)
- Active liver disease with coagulopathy
- Pregnancy
- Concomitant P-glycoprotein (P-gp) inhibitors in patients with CrCl <50 mL/min 2, 3, 1
Important caveat: Dabigatran is a substrate of the P-gp efflux transporter, requiring dose adjustments or avoidance with strong P-gp inhibitors, particularly in renal impairment 1